Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Debt Investor Presentation (September 2015)

41 slides from Sucampo Pharmaceuticals's debt investor presentation, Sep 21, 2015

  1. Slide 1: Lender Presentation

    Lender Presentation September 2015 € 3 SUCAMPO The Science of Innovation

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, including the statements relating to the expected benefits of the acquisition of R-Tech Ueno, statements about expected cost synergies,

  3. Slide 3: Note regarding Combined Financial Information and Use of Non-GAAP Financial Measures

    Note regarding Combined Financial Information and the Use of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures, which are presented to assist potential lenders in assessing Sucampo's and its subsidiaries’ current and future operations and ability to generate cash flo

  4. Slide 4: Management Presenters

    Management Presenters VN Peter Greenleaf, CEO * Served as CEO of Histogenics, a regenerative medicine company * Served as President of Medimmune, the global biologics arm of AstraZeneca - Instrumental in driving the expansion of MedImmune’s pipeline into over 120 clinical and pre-clinical programs a

  5. Slide 5: Agenda

    Agenda = Transaction Overview = Company Overview = Key Credit Highlights = Combined Company Overview " Historical Financial Overview = Syndication Overview ¢ 5 9 SUCAMPO The Science of Innovation

  6. Slide 6: Transaction Overview

    ¢ $ sucAMPO The Science of Innovation

  7. Slide 7: Executive Summary

    Executive Summary * On August 26, 2015, Sucampo Pharmaceuticals, Inc. (Nasdaq GM: SCMP) (‘Sucampo’ or the “Company” agreed to acquire R-Tech Ueno Ltd. (JASDAQ: 4573) (“RTU") for total consideration of JPY33 billion or approximately $278 million in cash - Sucampo announced a tender offer to acquire 5

  8. Slide 8: Sources and Uses and Capitalization

    ($ mitions) New Senior Secured Term Loan. Cash from Balance Sheet Total Sources. Cash and Cash Equivalents" Debt: Promissory Notes New Senior Secured Term Loan Total Debt Market Capitalization Total Capitalization (1) neues $584 millon of Sueapo investments and reticed cash, Combined cath balance ne

  9. Slide 9: Company Overview

    ympany Overview ¢ $ sucAMPO The Science of Innovation

  10. Slide 10: Sucampo: Global biopharmaceutical company focused on innovative R&D

    Global biopharmaceutical company focused on innovative R&D of proprictary drugs - Focused on gastrointestinal, ophthalmic, and oncology- based inflammatory disorders AMITIZA (lubiprostone), the Company's lead product, is a highly differentiated product with the broadest label in the constipation mar

  11. Slide 11: R-Tech Ueno: Global pharmaceutical company focused on research and development

    Global pharmaceutical company focused on the research and development of drugs in gastroenterology, ophthalmology and dermatology Exclusive manufacturer and supplier of AMITIZA and Resoula (unoprostone isopropyl) Manufacturing facility at Sanda City, Hyogo Prefecture, Japan — Specifically built to h

  12. Slide 12: Sucampo Evolution

    Sucampo Evolution 1989 1996 R-Tech Ueno, Ltd, Dr. Sachiko Kuno and Dr. Ueno established found RTU Ueno (USA), Ine., later to become Sucampo 2008 2009 2012 2013 AMITIZA AMITIZA AMITIZA AMITIZA approved approved approved for approved for for IBS-C for CIC in CIC intheUK lc inthe intheUS. Switzerland a

  13. Slide 13: Combined Business Overview

    ness Combination Key Products Areas Number of > Marketed Products Reena $133.6 million fevenue LT™ 6/30/15 7 Adjusted EBITDA $59.1 million RESCULA and other Revenue by Product aMTiZA 99% otter <1% X Tokeda Revenue by sta Partner saan 1% (2) Net ofintercompany etininatons. (@) neues $11.4 rion of coe

  14. Slide 14: Transaction rationale and highlights

    Favorable premium for the acquisition: ~30% pre-offer premium, ~16% premium to the pre- announcement 3 month volume weighted average price Attractive financial profile with the combined company generating strong, stable free cash flow Strong and immediate accretion from incorporating RTU's AMITIZA r

  15. Slide 15: Key Credit Highlights

    ¢ ] $ sucAMPO The Science of Innovation

  16. Slide 16: Key Credit Highlights (Cont'd)

    hlights (Cont'd) = Most expansive label in constipation market with 3 approved indications: CIC, IBS-C and OIC + Welltolerated product with established safety profile; no black box warning = Most experienced product with over 10 million prescriptions globally since 2006 = U.S. constipation market pr

  17. Slide 17: Key Credit Highlights (Cont'd)

    lights (Cont'd) + Robust patent portfolio with 49 issued patents relating to composition of matter, methods of use and methods of manufacturing expiring between 2020 and 2030 - 16 patents listed in the U.S. FDA Orange Book * Diversify product portfolio through new indications for AMITIZA and new cli

  18. Slide 18: Combined Company Overview

    ined Company Overview ¢ $ sucAMPO The Science of Innovation

  19. Slide 19: Significant unmet need in constipation market

    ‘Soares: IMS and Wall Sect research Significant unmet need in efficacy, safety and patient satisfaction U.S. prescription and OTC market ~$5.2 billion - $4.4 billion branded + generic market, ~50 million annual scripts “*) = Additional $800 million in revenue from OTC market, 23 million units (30-da

  20. Slide 20: Constipation market growth and indications

    + Infrequent and difficult passage of stool over 12 non-consecutive weeks within a 12-month @ bilions) si period CAGR: 7.7% sia = 33MM in U.S., 41MM in E.U., 15MM in Japan $122 (CC) siz as * Affects approximately 14% to 16% of adult population globally Disorder of the intestines with symptoms that -

  21. Slide 21: Unique and Highly Differentiated Product

    “ a Unique and Highly Differentiated Product = Most expansive label in constipation market: 3 indications, 3 patient types - CIC: Chronic Idiopathic Constipation Rag - IBS-C: Irritable Bowel Syndrome with Constipation Sez! , - OIC: Opioid Induced Constipation in adults (non-cancer) am iti Za = Only

  22. Slide 22: Accelerating prescription growth

    Accelerating prescription growth onan ‘Annualized (Thousands) ‘Annualized geese azzos,— T"owsond) 022015 1.482 4,920 az 1206 1245 18 pes tose 1110 1422 1488 i ead as ' 4241 490 185 8 2006 2007” 2008 2009 2010 2011 20122013 2014 LT 2 2012 2013, zou” LiMenons — a22015, 60/15 2015 so.g9 $1048 $1048 wpv

  23. Slide 23: Long history of usage

    —E—E—E——————————————————————_—————————E_ Long history of usage 1 of pee Sueampe 4, + Well tolerated among patient population wih song | 2t amitiza % (iStotcd ny tated) YX 8% enetration within elderly population i fog | lubiprostone ee Batts, Adit women _Alladuts «No Jimitation on durationofuse_ g =

  24. Slide 24: AMITIZA patent protection

    US. 934 Patent expires 2021 Composition of Matter L erpes 222 © (Product) Manufacturing U.S. 016, ‘613, ‘283, ‘562, ‘064 148, "653, '481, ‘312 >| Latest patent expires Latest patent expires 2027 2024 = AMITIZA is covered by an additional 10 patents through € 24 2028 in Japan and 6 patents in Europe

  25. Slide 25: Well-positioned to defend Amitiza IP

    w (Cont'd) Well-positioned to defend Amitiza IP = Successfully resolved patent litigation with = Sucampo has received a Paragraph IV Anchen Pharmaceuticals and Par certification notice letter regarding an Pharmaceuticals (collectively Par) for ANDA filed by Dr. Reddy's. Amitiza = Lawsuit claims infr

  26. Slide 26: Blue-chip partnerships providing global reach

    Blue-chip partnerships providing global reach Long-tenured partnership agreements with Takeda, Mylan and Harbin Gloria Strong relationship with Takeda since 2004 with 800 sales representatives currently marketing AMITIZA in U.S., Canada, U.K. and Switzerland - Takeda is #1 gastroenterology world wid

  27. Slide 27: AMITIZA growth drivers

    v Underpenetrated markets with unsatisfied patients Expanded Takeda agreement DTc OIC driving 30% of brand sales Physician Targeting v Yearly Increases Y Takeda + Net sales revenue split on brand lubiprostone, incl. LOM Y Gross-to-net cap for Sucampo Y Agreement with Par + Gross profit split on gene

  28. Slide 28: GI/Metabolic/Inflammation and Ophthalmology

    ‘Gi/Metabolic/ Inflammation ‘Ophthalmology ¢ 9 SUCAMPO The Science of Innovation

  29. Slide 29: Lifecycle Management

    Lifecycle Management Expand AMITIZA franchise through new formulation and new indication New Formulation = Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients = Incremental opportunity to address the roughly 40% of adults

  30. Slide 30: Diversify product portfolio through new clinical development

    Diversify product portfolio and pipeline through new clinical development and business development = Annually ~60,000 cases in U.S. and ~550,000 worldwide More than half of these are at advanced stage and treated with radiation 12,000 patients die from Head and Neck Cancer (HNC) yearly = No medicati

  31. Slide 31: Experienced Management Team

    ienced Management_Team Experienced management team with considerable experience in product development and commercialization @ristogenics —petrazenece> IML fohmensfoticn © centocor lal Bristol-Myers Squibb lal Amb Zyngenia araase ~ ESBATech micr@met bye Astrazenecs? i Vivus oe Ne i y) ser CT ee ane

  32. Slide 32: Historical Financial Overview

    rical Financial Overview ¢ $ sucAMPO The Science of Innovation

  33. Slide 33: Historical Revenue, Adjusted EBITDA and Free Cash Flow

    6 mitions) ” S755 sea 2012 2013, 2014 Lim ersos Sucampo ®RTU $39 $02 soa 8 “ — 2012 2013 2014 Utmenons 'Sucempo BRTU Free Cash Flow defined as Adjusted EBITDA less Capital Expenditures {assumes minimal capital expencitures for RTU) $100 $26.9 2012 === Sucampo 2012 ‘Sucempo 100% $961 on $48.0 mx $324

  34. Slide 34: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation (tions) 2012 2013 2014 LTM/s0r15| @ Intangible Assets Impairment Sucampo = Impairment related to Income from Operations s 83 $ 92 $ 272 $ a9 RESCULA outside Japan Depreciation and Amortization 15 15 14 06 . @ intangible Assets impairment - - 56 56 @ RESCULA Write-off ‘

  35. Slide 35: Syndication Overview

    ication Overview. ¢ $ sucAMPO The Science of Innovation

  36. Slide 36: Senior Secured Term Loan

    As — Senior Secured Term Hoan ‘Sucampo Pharmaceuticals, Inc. cility $250.0 million Senior Secured Term Loan (the “Term Loan") 1 6 years iz 5% annually with bullet at maturity 50% excess cash flow with step downs to 25% and 0% at TBD First Lien Net Leverage; 100% non-ordinary s course asset sale proc

  37. Slide 37: Corporate structure

    ‘Sucampo, AG (Switzerland) ‘Sucampo Pharma Europe, Ltd. (U.K.) € 7 3 SUCAMPO ° The Science of Innovation

  38. Slide 38: Syndication timetable

    Ss M Uf 1 6 7 8 13° 14 «15 20 21 22 27 28 «(29 October 15 October 12'* October 13" October 20*" Ww T F s Ss M T W T F s 2 3 4 5 2 3 9 10 11 12 4 5 6 7 8 9 10 16 17 18 «19 "1 14 15 16 17 23° 24 «25 26 18 19 Mm 21 22 23 24 30 25 26 27 28 29 #30 3 Bank meeting Receive commitments from lenders Tender of

  39. Slide 39: Appendix

    ¢ $ sucAMPO The Science of Innovation

  40. Slide 40: Income From Operations

    Income From Operations (Smiions) 2013 2014 LTM6/30/15 ‘Sucampo Income from Operations S$ 838 928 m28 19 RTU Income from Operations $ 29S 13S 18S 145 $ sucampo 40 The S

  41. Slide 41: Free Cash Flow Reconciliation

    Free Cash Flow Reconciliation (S miions) 2012 2013 2014 LTM@/30/5) ‘Sucampo Adjusted EBITDA $ 1208 69 $ 328 501 = Capital Expenditures, 69) (0.2) (0.1) (0.1) ‘Sucampo Free Cash Flow $ 82$ 68S 328 591 RTU Adjusted EBITDA S$ 48$ 628 17 $8 156 = Capital Expenditures, : : : 4) RTU Free Cash Flow S$ 48S

Sucampo Pharmaceuticals — Debt Investor Presentation (September 2015) on 6ix